2-甲基-5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯 | 478375-39-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯
• 中文别名: 3-(甲氧基羰基)-4-甲基苯基硼酸频哪醇酯
• 英文名称: methyl 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
• CAS: 478375-39-2
• 化学式: C₁₅H₂₁BO₄
• 分子量: 276.14
• InChiKey: WBHBKJFHYGIUQU-UHFFFAOYSA-N

物化性质

• 沸点：
  370.4±35.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.08
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(Methoxycarbonyl)-4-methylphenylboronic acid, pinacol ester
Synonyms: Methyl 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Methoxycarbonyl)-4-methylphenylboronic acid, pinacol ester
CAS number: 478375-39-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H21BO4
Molecular weight: 276.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  5-硼酸基-2-甲基苯甲酸甲酯	(3-(methoxycarbonyl)-4-methylphenyl)boronic acid	1048330-10-4	C9H11BO4	193.995
  1-异吲哚酮-6-硼酸频哪醇酯	6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one	1004294-80-7	C14H18BNO3	259.113
  2-甲基-6-(4,4,5,5-四甲基-1,3,2-二氧硼戊烷-2-基)异吲哚啉-1-酮	2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one	1313399-38-0	C15H20BNO3	273.14

反应信息

• 作为反应物：
  描述：

  2-甲基-5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯 在 甲醇 、 sodium hydroxide 、 sodium periodate 、 ammonium acetate 、 水 、 copper diacetate 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 17.0h， 生成
  参考文献：
  名称：

  Discovery of a Novel Series of Benzoic Acid Derivatives as Potent and Selective Human β₃ Adrenergic Receptor Agonists with Good Oral Bioavailability. 3. Phenylethanolaminotetraline (PEAT) Skeleton Containing Biphenyl or Biphenyl Ether Moiety

  摘要：

  We designed a series of benzoic acid derivatives containing the biphenyl ether or biphenyl template on the RHS and a phenylethanolaminotetraline (PEAT) skeleton, which was prepared by highly stereoselective synthesis, to generate two structurally different lead compounds (10c, 10m) with a good balance of potency, selectivity, and pharmacokinetic profile. Further optimization of the two lead compounds to improve potency led to several potential candidates (i.e., 11f, 11l, 11o, 12b). In particular, biphenyl analogue 12b exhibited an excellent balance of high potency (EC(50) = 0.38 nM) for beta(3), high selectivity over beta(1) and beta(2), and good pharmacokinetic properties in rats, dogs, and monkeys.

  DOI：

  10.1021/jm800222k
• 作为产物：
  描述：

  2-甲基-5-溴苯甲酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 氯化亚砜 、 potassium acetate 作用下， 以 甲醇 为溶剂， 反应 10.0h， 生成 2-甲基-5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯
  参考文献：
  名称：

  含苯并五元杂环结构的化合物及其制备方法与用途

  摘要：

  本发明涉及药物化学领域，公开了一类含苯并五元杂环结构的化合物及其制备方法与用途。本发明还公开了含有所述苯并五元杂环化合物或其药学上可接受的盐及药学上可接受的载体的组合物、及其在制备PARP‑1和ERK抑制剂中的用途。本发明的化合物可用于治疗肿瘤等疾病。

  公开号：

  CN113248482B

文献信息

• [EN] METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS<br/>[FR] PROCÉDÉS, PROCESSUS ET INTERMÉDIAIRES POUR LA PRÉPARATION DE COMPOSÉS CHROMANE
  申请人：LUPIN LTD

  公开号：WO2021144814A1

  公开（公告）日：2021-07-22

  This disclosure describes an economical and scalable method and process to synthesize the Calcium sensing receptor (CaSR) modulating agent 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates and pharmaceutically acceptable salts therefor. Uses of said intermediates for synthesis of compounds which may be intermediates to the synthesis of 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid are also described herein.

  这份披露描述了一种经济且可扩展的方法和过程，用于合成钙感测受体（CaSR）调节剂2-甲基-5-((2R,4S)-2-((((R)-1-(萘-1-基)乙基)氨基)甲基)香豆素-4-基)苯甲酸，及其中间体和药用可接受的盐。还描述了所述中间体用于合成可能是2-甲基-5-((2R,4S)-2-((((R)-1-(萘-1-基)乙基)氨基)甲基)香豆素-4-基)苯甲酸合成中间体的化合物的用途。
• [EN] AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS<br/>[FR] AMINOPYRROLOTRIAZINES EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019147782A1

  公开（公告）日：2019-08-01

  The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

  该公开涉及到公式I的化合物，这些化合物可用作激酶调节剂，包括RIPK1调节。该公开还提供了制备和使用这些化合物的方法，例如在涉及坏死或炎症以及其他适应症的治疗中使用。
• [EN] PI4KIIIBETA INHIBITORS<br/>[FR] INHIBITEURS DE PI4KIIIBÊTA
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019141694A1

  公开（公告）日：2019-07-25

  The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.

  这项发明涉及式(I)的化合物，这些化合物是激酶活性的抑制剂，包含这些化合物的药物配方以及它们在治疗和预防病毒感染及由病毒感染引起或加重的疾病中的用途，其中R1、R2、R3、R4a、R4b、R4c、R5、W、X、Y和Z在此处定义。
• [EN] BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS BENZOLACTAMES UTILISÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2017068412A1

  公开（公告）日：2017-04-27

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof. The compounds are inhibitors of ERK 1/2 kinases and will be useful in the treatment of ERKl/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

  该发明提供了一个化合物，其化学式为(0)：或其药学上可接受的盐、N-氧化物或互变异构体。这些化合物是ERK 1/2激酶的抑制剂，并将在治疗ERKl/2介导的疾病中发挥作用。因此，这些化合物在治疗中特别是在癌症治疗中是有用的。
• Photo-induced thiolate catalytic activation of inert Caryl-hetero bonds for radical borylation
  作者：Shun Wang、Hua Wang、Burkhard König

  DOI：10.1016/j.chempr.2021.04.016

  日期：2021.6

  the activation of bonds with high bond dissociation energy and to substrates with high reduction potentials. Herein, we introduce a novel photocatalytic strategy for the activation of inert substituted arenes for aryl borylation by using thiolate as a catalyst. This catalytic system exhibits strong reducing ability and engages non-activated Caryl–F, Caryl–X, Caryl–O, Caryl–N, and Caryl–S bonds in productive

  目前正致力于获得具有高氧化还原能力的光氧化还原催化剂。然而，将目前建立的方法应用于具有高键离解能的键的活化和具有高还原电位的基材仍然具有挑战性。在此，我们介绍了一种新的光催化策略，通过使用硫醇盐作为催化剂来活化惰性取代芳烃以进行芳基硼化。该催化体系具有很强的还原能力，可与未活化的C芳基-F、C芳基-X、C芳基-O、C芳基-N和C芳基结合-S 键用于生产性自由基硼化反应，从而扩大了可用的芳基自由基前体范围。尽管具有很高的还原能力，但该方法具有广泛的底物范围和良好的官能团耐受性。光谱研究和控制实验表明，电荷转移复合物的形成是激活底物的关键步骤。